Financials Treace Medical Concepts, Inc.
Equities
TMCI
US89455T1097
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.05 USD | -2.13% | +1.61% | -60.39% |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
May. 16 | UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16 | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 991.1 | 1,276 | 786.4 | 319.9 | - | - |
Enterprise Value (EV) 1 | 914.8 | 1,247 | 716.2 | 322 | 354.7 | 381 |
P/E ratio | -43.3 x | -29.9 x | -15.7 x | -5.71 x | -6.09 x | -6.65 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 10.5 x | 9 x | 4.2 x | 1.56 x | 1.39 x | 1.25 x |
EV / Revenue | 9.69 x | 8.79 x | 3.83 x | 1.57 x | 1.54 x | 1.49 x |
EV / EBITDA | -73.7 x | -52.7 x | -29.4 x | -21.4 x | -55.4 x | -837 x |
EV / FCF | -46 x | -27.4 x | -15.6 x | -11.1 x | -12.2 x | -16.6 x |
FCF Yield | -2.18% | -3.65% | -6.43% | -9.01% | -8.18% | -6.04% |
Price to Book | 10.9 x | 21.1 x | 5.62 x | 2.69 x | 3.38 x | 4.27 x |
Nbr of stocks (in thousands) | 53,173 | 55,502 | 61,676 | 61,989 | - | - |
Reference price 2 | 18.64 | 22.99 | 12.75 | 5.160 | 5.160 | 5.160 |
Announcement Date | 3/3/22 | 3/7/23 | 2/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 57.36 | 94.42 | 141.8 | 187.1 | 205.5 | 229.8 | 256.2 |
EBITDA 1 | - | -12.42 | -23.69 | -24.39 | -15.03 | -6.398 | -0.4553 |
EBIT 1 | - | -16.51 | -34.84 | -51.43 | -56.16 | -50.55 | -46.81 |
Operating Margin | - | -17.49% | -24.57% | -27.48% | -27.33% | -22% | -18.27% |
Earnings before Tax (EBT) 1 | - | -20.55 | -42.82 | -49.53 | -56.32 | -50.17 | -44.35 |
Net income 1 | - | -20.75 | -42.82 | -49.53 | -55.48 | -51.31 | -46.55 |
Net margin | - | -21.97% | -30.19% | -26.47% | -27% | -22.33% | -18.17% |
EPS 2 | -0.1196 | -0.4300 | -0.7700 | -0.8100 | -0.9042 | -0.8473 | -0.7762 |
Free Cash Flow 1 | - | -19.9 | -45.49 | -46.03 | -29 | -29 | -23 |
FCF margin | - | -21.07% | -32.07% | -24.6% | -14.11% | -12.62% | -8.98% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 3/30/21 | 3/3/22 | 3/7/23 | 2/27/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 33.44 | 29.05 | 29.97 | 33.06 | 49.77 | 42.2 | 41.95 | 40.76 | 62.21 | 51.11 | 43.01 | 43.95 | 67.69 | 54.82 | 49.22 |
EBITDA 1 | -4.028 | -6.353 | -9.419 | -8.215 | 0.286 | -10.03 | -7.746 | -9.237 | 2.629 | -8.26 | -8.023 | -6.402 | 7.897 | -7.981 | -5.381 |
EBIT 1 | -5.597 | -8.096 | -11.93 | -11.32 | -3.497 | -13.78 | -13.05 | -17.82 | -6.782 | -18.97 | -17.96 | -15.74 | -3.449 | -18.99 | -15.84 |
Operating Margin | -16.74% | -27.87% | -39.82% | -34.24% | -7.03% | -32.65% | -31.11% | -43.72% | -10.9% | -37.11% | -41.76% | -35.82% | -5.09% | -34.64% | -32.17% |
Earnings before Tax (EBT) 1 | -6.619 | -9.036 | -17.23 | -12.13 | -4.412 | -13.45 | -12.27 | -17.52 | -6.281 | -18.68 | -18.97 | -16.14 | -2.488 | -19.02 | -15.81 |
Net income 1 | -6.619 | -9.036 | -17.23 | -12.13 | -4.412 | -13.45 | -12.27 | -17.52 | -6.281 | -18.68 | -18.37 | -15.51 | -2.59 | -19.02 | -15.81 |
Net margin | -19.79% | -31.11% | -57.51% | -36.71% | -8.86% | -31.89% | -29.25% | -42.99% | -10.1% | -36.54% | -42.72% | -35.29% | -3.83% | -34.7% | -32.11% |
EPS 2 | -0.1200 | -0.1600 | -0.3100 | -0.2200 | -0.0800 | -0.2300 | -0.2000 | -0.2800 | -0.1000 | -0.3000 | -0.2908 | -0.2570 | -0.0531 | -0.2872 | -0.2473 |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/3/22 | 5/5/22 | 8/9/22 | 11/8/22 | 3/7/23 | 5/8/23 | 8/8/23 | 11/9/23 | 2/27/24 | 5/7/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 2.1 | 34.8 | 61.1 |
Net Cash position 1 | - | 76.3 | 28.5 | 70.2 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | -0.1398 x | -5.438 x | -134.3 x |
Free Cash Flow 1 | - | -19.9 | -45.5 | -46 | -29 | -29 | -23 |
ROE (net income / shareholders' equity) | - | -44.2% | -55.7% | -49.9% | -43.4% | -55.6% | -66.9% |
ROA (Net income/ Total Assets) | - | -22.7% | -28.6% | -24.1% | -18.5% | -19.2% | -17.7% |
Assets 1 | - | 91.31 | 149.9 | 205.5 | 299.9 | 266.7 | 262.8 |
Book Value Per Share 2 | - | 1.720 | 1.090 | 2.270 | 1.920 | 1.530 | 1.210 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 2.71 | 14.8 | 11.5 | 12.8 | 13.7 | 16.4 |
Capex / Sales | - | 2.86% | 10.46% | 6.12% | 6.25% | 5.97% | 6.38% |
Announcement Date | 3/30/21 | 3/3/22 | 3/7/23 | 2/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.39% | 320M | |
+75.56% | 12.55B | |
-23.35% | 7.51B | |
+8.51% | 6.74B | |
+14.95% | 5.48B | |
-14.65% | 4.93B | |
+30.59% | 4.71B | |
-24.40% | 3.83B | |
-22.61% | 2.9B | |
+49.50% | 2.49B |
- Stock Market
- Equities
- TMCI Stock
- Financials Treace Medical Concepts, Inc.